ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,211.60
0.78%
S&P 500
5,308.08
0.09%
US Dollar vs CAD
1.36215
0.10%
Bitcoin
69,764.54
5.27%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AN2 Therapeutics Inc (ANTX)

  7. AN2 Therapeutics Inc (ANTX) News

ANTX

AN2 Therapeutics (ANTX)

AN2 Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ANTX
DateTimeSourceHeadlineSymbolCompany
05/14/20243:12PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
05/14/20243:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
05/14/20243:01PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ANTXAN2 Therapeutics Inc
05/14/20243:01PMBusiness WireAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
03/28/20243:10PMBusiness WireAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
02/13/20244:11PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANTXAN2 Therapeutics Inc
02/12/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
02/12/20245:45AMBusiness WireAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
01/30/20243:10PMBusiness WireAN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
01/18/20245:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/17/20244:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/12/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/11/20246:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/04/20245:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/04/20245:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/02/20243:45PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/02/20243:36PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
11/16/20235:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
11/09/20233:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
11/09/20233:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
11/09/20233:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
11/09/20233:05PMBusiness WireAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
11/06/20236:00AMBusiness WireAN2 Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ANTXAN2 Therapeutics Inc
10/18/20236:00AMBusiness WireAN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
10/10/202311:01PMBusiness WireAN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023NASDAQ:ANTXAN2 Therapeutics Inc
10/03/20236:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
10/02/20233:10PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
09/29/20234:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
09/29/20233:11PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
09/26/20236:00AMBusiness WireAN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and MalariaNASDAQ:ANTXAN2 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ANTX

Your Recent History

COIN
TRAKEUR
TrakInvest
BITMOT
987577
Eib Tf 0,25% Ge32 Eur
TSX
CALL.B
Evolve US Banks Enchance...
EU
U198S
U198S
BIT
P1SCA9
NLBNPIT1SCA9 20241220 320
BIT
P1Z3D0
NLBNPIT1Z3D0 20351221 0....
USOTC
BOMBF
Bombardier (PK)
COIN
MXTBTC
USOTC
DSCNF
Datasection (GM)
NASDAQ
KNGZ
First Trust VI S&P 500 D...
KUCN
RDNTUSDT
Radiant
BITMOT
885315
Eib Tf 2,9% Ot25 Aud
ASX
MQGSSI
UNSW
FRENSETH
Fren.community
NYSE
ARNC.PRB
Arconic Inc.
COIN
ARMORUSD
Armor
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved